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Thirty- the promise of a decade of loneliness, a thinning list of single 
men to know, a thinning briefcase of enthusiasm, thinning hair- F. Scott 
Fitzgerald
Omeprazole was discovered in 1979 and became part of most 
formularies for routine use in the late 1980s. It is a member of the proton 
pump inhibitor (PPI) family, a class of medications used to suppress 
gastric acid secretion from parietal cells. Proton pump inhibitors are 
used for stress ulcer prophylaxis and to treat gastroesophageal reflux 
(GERD), dyspepsia, and peptic ulcer disease (PUD). Once widely 
touted for efficacy and safety, omeprazole and other medications 
in this class have experienced some stumbling blocks in their third 
decade. Emergent data has demonstrated several adverse effects, 
including osteoporotic fractures, pneumonia, vitamin B12 deficiency, 
hypomagnesemia, and Clostridium difficile associated diarrhea. This list 
has been growing steadily, particularly in the last ten years. For patients 
with severe PUD or an elevated risk of Barrett’s esophagus, these 
medications can be extremely helpful. Unfortunately, many patients 
take PPIs for years without having a clear indication to do so. Only 50% 
of those who are taking maintenance PPI therapy have an appropriately 
documented indication [1]. 
Chronic acid suppression has been linked to nutritional deficiencies 
as well as electrolyte abnormalities. Lam JR, et al, demonstrated a 
significant increase in vitamin B12 deficiency for those taking PPIs for 
2 or more years [2]. As is true for most of the potential adverse effects of 
PPI therapy, this risk is exacerbated by prolonged use and higher dosages. 
Hypomagnesemia has been correlated to PPI use and is of particular 
concern for those who have been taking PPIs for several years [3,4]. 
This risk of hypomagnesemia is further increased by concurrent use of 
thiazide and loop diuretic medications [5]. Osteoporotic fractures are 
also more prevalent following PPI use secondary to interference with 
calcium absorption and bone resorption. Patients who have been taking 
PPIs for greater than one year are 1½ times more likely to experience 
an osteoporotic fracture than those who are not taking medications to 
suppress gastric acid secretion [6-8]. 
Proton pump inhibitors have been linked to pulmonary and 
gastrointestinal infections, potentially as a result of increased gastric pH 
and bacterial overgrowth. The risk of community-acquired pneumonia 
has been correlated to PPI use, although further randomized controlled 
trials are needed to confirm this [9]. PPIs have also been found to 
increase the risk of enteric infections. Most notable is Clostridium 
difficile associated diarrhea, with a five-fold increase in risk for those 
who are taking PPIs twice daily in addition to antibiotics [10,11]. 
Additionally, recent studies have demonstrated an increased risk of 
Salmonella and Campylobacter jejuni infections with concurrent PPI 
use [12,13].
Based upon the list of newly recognized adverse effects, it appears 
that like many medications, PPIs are not entirely benign. We encourage 
vigilance and careful consideration before renewing prescriptions 
for PPIs without discussion of indication and current symptoms. 
We also recommend attempts to optimize symptom control for 
uncomplicated GERD, gastritis, and PUD with lifestyle modifications, 
weight loss, limited NSAID use, and treatment of Helicobacter pylori 
when indicated. Abruptly discontinuing PPIs may result in a relapse 
of symptoms, which does not necessarily mean that they are indicated 
indefinitely. On demand therapy of PPIs, tapering of dosages, and step-
down therapy to histamine 2 receptor antagonists may be considered 
to decrease the incidence of symptom recurrence [14]. There are, of 
course, patients who will have appropriate indications for maintenance 
PPI therapy [15]. For those who do require maintenance therapy, we 
recommend the lowest possible doses of efficacious medications to 
decrease the risk of the above adverse effects.
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